Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Farxiga® (dapagliflozin) – Expanded indication
May 9, 2023 - AstraZeneca announced the FDA approval of Farxiga (dapagliflozin), to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
